JP2023553976A - がんを治療するための材料及び方法 - Google Patents

がんを治療するための材料及び方法 Download PDF

Info

Publication number
JP2023553976A
JP2023553976A JP2023535631A JP2023535631A JP2023553976A JP 2023553976 A JP2023553976 A JP 2023553976A JP 2023535631 A JP2023535631 A JP 2023535631A JP 2023535631 A JP2023535631 A JP 2023535631A JP 2023553976 A JP2023553976 A JP 2023553976A
Authority
JP
Japan
Prior art keywords
composition
kit
cancer
component
mitomycin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023535631A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023553976A5 (https=
JPWO2022123480A5 (https=
Inventor
ハイオニディ,ユリア
ティシポリ,オメル
コノーティ,マリナ
Original Assignee
ウロゲン ファーマ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウロゲン ファーマ リミテッド filed Critical ウロゲン ファーマ リミテッド
Publication of JP2023553976A publication Critical patent/JP2023553976A/ja
Publication of JP2023553976A5 publication Critical patent/JP2023553976A5/ja
Publication of JPWO2022123480A5 publication Critical patent/JPWO2022123480A5/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023535631A 2020-12-11 2021-12-09 がんを治療するための材料及び方法 Pending JP2023553976A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063124111P 2020-12-11 2020-12-11
US63/124,111 2020-12-11
PCT/IB2021/061499 WO2022123480A1 (en) 2020-12-11 2021-12-09 Material and method for treating cancer

Publications (3)

Publication Number Publication Date
JP2023553976A true JP2023553976A (ja) 2023-12-26
JP2023553976A5 JP2023553976A5 (https=) 2024-12-13
JPWO2022123480A5 JPWO2022123480A5 (https=) 2024-12-13

Family

ID=78916713

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023535631A Pending JP2023553976A (ja) 2020-12-11 2021-12-09 がんを治療するための材料及び方法

Country Status (6)

Country Link
US (2) US12336979B2 (https=)
EP (1) EP4259093B1 (https=)
JP (1) JP2023553976A (https=)
KR (1) KR20230118632A (https=)
CA (1) CA3201129A1 (https=)
WO (1) WO2022123480A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10471150B2 (en) 2010-01-20 2019-11-12 Urogen Pharma Ltd. Material and method for treating internal cavities
US12336979B2 (en) 2020-12-11 2025-06-24 Urogen Pharma Ltd. Material and method for treating cancer
US20240100019A1 (en) * 2022-09-28 2024-03-28 Urogen Pharma Ltd. Compositions comprising a thermoreversible hydrogel, and having an extended in-use period
EP4713013A1 (en) 2023-05-16 2026-03-25 UroGen Pharma Ltd. Immunomodulating treatments of body cavities
KR20260043121A (ko) 2023-07-25 2026-03-31 우로젠 파마 엘티디. 미토마이신을 함유하는 열 겔화 제약 조성물을 사용한 저등급 중간-위험 비근침습성 방광암의 치료
CN121729785A (zh) 2023-09-06 2026-03-24 株式会社Lg新能源 袋用片材、袋型电池盒以及用于制造电池盒的方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011089604A2 (en) * 2010-01-20 2011-07-28 Theracoat Ltd Material and method for treating internal cavities
WO2013011504A1 (en) * 2011-07-20 2013-01-24 Theracoat Ltd. Materials and method for treating internal body cavities
JP2016534060A (ja) * 2013-10-22 2016-11-04 メダック ゲゼルシャフト フィア クリニッシェ スペツィアルプレパラーテ ミット ベシュレンクタ ハフトゥンク ある含有量のマイトマイシンcを有する凍結乾燥医薬組成物を製造する方法
US9801854B1 (en) * 2014-01-17 2017-10-31 Urogen Pharma Ltd. Slow release formulations of cell cycle regulators and anti-cancer agents for local treatment of solid cancer
EP3498270A1 (en) * 2017-10-30 2019-06-19 Urogen Pharma Ltd. Slow release formulations of cell cycle regulators and anti-cancer agents for local treatment of solid cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0386960A3 (en) 1989-03-07 1991-10-23 American Cyanamid Company Pharmaceutical compositions useful as drug delivery vehicles and/or as wound dressings
US5861174A (en) 1996-07-12 1999-01-19 University Technology Corporation Temperature sensitive gel for sustained delivery of protein drugs
US6286513B1 (en) 1998-10-22 2001-09-11 Jessie L. Au Methods for treating superficial bladder carcinoma
US20040009212A1 (en) 2002-01-30 2004-01-15 Pharma Power Biotec Co. Ltd. Mucoadhesive thermoresponsive medicament-carrier composition
GB0328060D0 (en) 2003-12-04 2004-01-07 Sod Conseils Rech Applic Botulinum toxin treatment
GB0414825D0 (en) 2004-07-02 2004-08-04 Biostatus Ltd Gel formulations and uses thereof
US20090142259A1 (en) 2006-05-12 2009-06-04 Genentech, Inc. Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors
US9107815B2 (en) 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
EP2313122B1 (en) 2008-07-17 2019-03-06 Micell Technologies, Inc. Drug delivery medical device
US10471150B2 (en) 2010-01-20 2019-11-12 Urogen Pharma Ltd. Material and method for treating internal cavities
US20140142191A1 (en) 2011-07-20 2014-05-22 Theracoat Ltd. Production of thermoreversible hydrogels for therapeutic applications
WO2016004213A2 (en) 2014-07-01 2016-01-07 Vicus Therapeutics, Llc Hydrogels for treating and ameliorating cancers and potentiating the immune system and methods of making and using them
US20170128424A1 (en) 2015-11-11 2017-05-11 Qrono, Inc. Sustained release pharmaceutical compositions and methods of use
JP7265989B2 (ja) * 2016-10-25 2023-04-27 ウロゲン ファーマ リミテッド 体腔の免疫調節治療
WO2018169960A1 (en) 2017-03-17 2018-09-20 The Johns Hopkins University Nanoparticle formulations for enhanced drug delivery to the bladder
US12336979B2 (en) 2020-12-11 2025-06-24 Urogen Pharma Ltd. Material and method for treating cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011089604A2 (en) * 2010-01-20 2011-07-28 Theracoat Ltd Material and method for treating internal cavities
WO2013011504A1 (en) * 2011-07-20 2013-01-24 Theracoat Ltd. Materials and method for treating internal body cavities
JP2016534060A (ja) * 2013-10-22 2016-11-04 メダック ゲゼルシャフト フィア クリニッシェ スペツィアルプレパラーテ ミット ベシュレンクタ ハフトゥンク ある含有量のマイトマイシンcを有する凍結乾燥医薬組成物を製造する方法
US9801854B1 (en) * 2014-01-17 2017-10-31 Urogen Pharma Ltd. Slow release formulations of cell cycle regulators and anti-cancer agents for local treatment of solid cancer
EP3498270A1 (en) * 2017-10-30 2019-06-19 Urogen Pharma Ltd. Slow release formulations of cell cycle regulators and anti-cancer agents for local treatment of solid cancer

Also Published As

Publication number Publication date
KR20230118632A (ko) 2023-08-11
CA3201129A1 (en) 2022-06-16
US20240108603A1 (en) 2024-04-04
EP4259093A1 (en) 2023-10-18
EP4259093B1 (en) 2025-08-13
US20220202773A1 (en) 2022-06-30
US12171747B2 (en) 2024-12-24
US12336979B2 (en) 2025-06-24
WO2022123480A1 (en) 2022-06-16

Similar Documents

Publication Publication Date Title
US12171747B2 (en) Material and method for treating cancer
US20230241221A1 (en) Material and method for treating internal cavities
JP7810753B2 (ja) 液体送達組成物
EP2525777B1 (en) Material and method for treating internal cavities
JP2001526246A (ja) 薬剤送達及び/又は癒着防止のための方法及び組成物
KR20180103039A (ko) 방광암 치료용 제제
CN1861041B (zh) 局部注射用温敏型缓释凝胶剂及制备方法
KR102144615B1 (ko) 폴리데옥시리보뉴클레오타이드를 포함하는 마이셀, 약물 전달체 및 이의 제조방법
WO2017046369A1 (en) Gelling compositions for treating malignant tumours and/or preventing tumour recurrence
CN101933897B (zh) 注射用重组人血管内皮抑制素温度敏感性凝胶组合物
KR102455423B1 (ko) 펜벤다졸 가용화 조성물 및 이의 용도
KR20190084284A (ko) 상부요로상피암종의 치료 방법
KR101010411B1 (ko) 온단세트론의 직장내 투여를 위한 온도 감응성 액상좌제조성물
CN101816777B (zh) 新颖的博安霉素组合物及其制备方法
WO2024194781A1 (en) Improved compositions
JP2004131472A (ja) 痔疾治療用軟膏
CN105342984A (zh) 一种用于治疗急性胰腺炎的可注射温敏凝胶制剂
CN121796322A (zh) 秋水仙碱外用纳米乳胶剂及其制备方法与应用
WO2025153747A1 (es) Composiciones y esquemas de dosificación de inhibidores de aromatasa mejorados
HK1255212B (zh) 用於治疗膀胱癌的制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241205

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260306